Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Recruiting Phase 1 Trials for Tegavivint (DB17109)

IndicationStatusPhase
DBCOND0153038 (Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05755087Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell LymphomaTreatment